Tectonic registers Phase 1b trial of TX002100 for transfusion-dependent HHT
Tectonic Operating Company listed a new Phase 1b study testing TX002100 in hereditary hemorrhagic telangiectasia patients who depend on blood or iron support.
Tectonic Operating Company registered one new trial this week.
- TX002100, a biological given by weekly subcutaneous injection, is being studied in a Phase 1b trial for hereditary hemorrhagic telangiectasia (HHT) in patients needing regular hematologic support. The study, sponsored by Tectonic Operating Company, Inc., is listed as not yet recruiting, with an estimated start date of 2027-01-311. The trial plans to enroll 20 participants1 and will assess whether TX002100 reduces the need for blood or iron treatments, and whether it improves blood counts, such as hemoglobin levels1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.